Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Treasury Shares: 2021-2025

Historic Treasury Shares for GeneDx Holdings (WGS) over the last 4 years, with Sep 2025 value amounting to $1.6 million.

  • GeneDx Holdings' Treasury Shares fell 24.75% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 24.75%. This contributed to the annual value of $1.9 million for FY2024, which is 23.99% up from last year.
  • As of Q3 2025, GeneDx Holdings' Treasury Shares stood at $1.6 million, which was down 3.16% from $1.6 million recorded in Q2 2025.
  • Over the past 5 years, GeneDx Holdings' Treasury Shares peaked at $23.7 million during Q3 2022, and registered a low of $855,061 during Q4 2022.
  • Over the past 3 years, GeneDx Holdings' median Treasury Shares value was $1.8 million (recorded in 2025), while the average stood at $1.8 million.
  • In the last 5 years, GeneDx Holdings' Treasury Shares plummeted by 93.21% in 2022 and then soared by 76.35% in 2023.
  • Quarterly analysis of 5 years shows GeneDx Holdings' Treasury Shares stood at $12.6 million in 2021, then tumbled by 93.21% to $855,061 in 2022, then spiked by 76.35% to $1.5 million in 2023, then rose by 23.99% to $1.9 million in 2024, then decreased by 24.75% to $1.6 million in 2025.
  • Its Treasury Shares stands at $1.6 million for Q3 2025, versus $1.6 million for Q2 2025 and $1.8 million for Q1 2025.